BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/18/2016 2:28:00 PM | Browse: 1160 | Download: 2198
Publication Name World Journal of Transplantation
Manuscript ID 19468
Country United States
ISSN 2220-3230 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Transplantation
Manuscript Type Case Report
Article Title Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation
Manuscript Source Unsolicited Manuscript
All Author List Khawaja S Zaki, Zahra Aryan, Atul C Mehta, Olufemi Akindipe and Marie Budev
Funding Agency and Grant Number
Corresponding Author Atul C Mehta, MD, FACP, FCCP, Professor of Medicine, Staff, Lerner College of Medicine, Bouncore Family Endowed Chair in Lung Transplantation, Cleveland Clinic, 2049 E 100th St, Cleveland, OH 44195, United States. mehtaa1@ccf.org
Key Words Lymphangioleiomyomatosis; Mammalian target of rapamycin inhibitors; Lung transplantation; Sirolimus; Lung rejection
Core Tip Lymphangioleiomyomatosis (LAM) is a rare, slowly progressive lethal lung disease characterized by proliferation of abnormal smooth muscle cells that target the lungs, causing cystic destruction and eventual respiratory failure and death. Mammalian target of rapamycin (mTOR) inhibitors such as sirolimus have shown promise in stabilization of lung function. Lung transplantation is a viable option when lung function continues to decline despite use of mTOR inhibitors. However, recurrence of LAM in transplanted lung has been reported. We describe a case of LAM recurrence in a bilateral lung transplant recipient nine years after transplantation, our therapeutic approach once recurrence was documented with review of the literature.
Publish Date 2016-03-18 14:28
Citation Zaki KS, Aryan Z, Mehta AC, Akindipe O, Budev M. Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation. World J Transplant 2016; 6(1): 249-254
URL http://www.wjgnet.com/2220-3230/full/v6/i1/249.htm
DOI http://dx.doi.org/10.5500/wjt.v6.i1.249
Full Article (PDF) WJT-6-249.pdf
Full Article (Word) WJT-6-249.doc